Adagio Therapeutics : Announces ADG20 (adintrevimab) is the First Monoclonal Antibody to Meet Primary Endpoints with Statistical Significance Across Pre- and Post-exposure Prophylaxis and Treatment for COVID-19 and Plans to Seek U.S. Emergency Use Authorization - Form 8-K

Adagio Therapeutics Announces ADG20 is the First Monoclonal Antibody to Meet Primary Endpoints with Statistical Significance Across Pre- and Post-exposure Prophylaxis and Treatment... | March 30, 2022

Related Keywords

,Ellie Hershberger ,Dan Budwick ,Monique Allaire ,David Hering ,Additional Development ,Adagio Therapeutics Inc ,Drug Administration ,Division Of Organ Transplantation ,Division Of Infectious Diseases ,Nasdaq ,Northwestern University Feinberg School Of Medicine ,Exchange Commission ,Strategic Communications ,Research Updates ,Adagio Therapeutics Announces ,First Monoclonal Antibody ,Meet Primary Endpoints ,Statistical Significance Across ,Post Exposure Prophylaxis ,Emergency Use Authorization ,Infectious Diseases ,Organ Transplantation ,Northwestern University Feinberg School ,Fourth Quarter ,Financial Guidance ,Private Securities Litigation Reform Act ,Convertible Preferred Stock ,Stockholder Equity ,Adagio Therapeutics ,Nc Stock Exchange ,News ,Information ,Press Release ,Adagio ,Herapeutics ,Nnounces ,Dg20 ,Us ,The ,First ,Monoclonal ,Ntibody ,O ,Feet ,Primary ,Endpoints ,Ith ,Tatistical ,Significance ,Cross ,End ,Prophylaxis ,Nd Adgi Us00534a1025 ,